Antiproliferative effects of imidazo[1,2-a]pyrazine derivatives on the Dami cell line

Biochemical Pharmacology

Volumn 54, Issue 3, 1997, Pages 365-371

  Zurbonsen, Katja ^a   Michel, Alain ^b   Vittet, Daniel ^a   Bonnet, Pierre Antoine ^b   Chevillard, Claude ^a  

^a INSERM   (France)

^b UNIV MONTPELLIER   (France)

Author keywords

cAMP; Imidazo 1,2 a pyrazines; Megakaryoblastes; PDE isoenzymes; Proliferation; Purinoceptors

Indexed keywords

CYCLIC AMP; IMIDAZOPYRAZINE DERIVATIVE; ISOBUTYLMETHYLXANTHINE; ISOENZYME; PHOSPHODIESTERASE; PROSTAGLANDIN E1;

ARTICLE; CELL CULTURE; CELL GROWTH; CELL LINE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPOPHILICITY; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

1-METHYL-3-ISOBUTYLXANTHINE; ALPROSTADIL; CELL DIVISION; CELL SURVIVAL; CYCLIC AMP; IMIDAZOLES; PHOSPHORIC DIESTER HYDROLASES; PYRAZINES; PYRIDAZINES; RECEPTORS, PURINERGIC P2; TUMOR CELLS, CULTURED;

EID: 0030823274     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00224-4     Document Type: Article

References (36)

1. Boynton AL and Whitfield JF, The role of cyclic AMP in cell proliferation: a critical assessment of the evidence. Adv Cyclic Nucleotide Res 15: 193-294, 1983.
2. Dumont JE, Jauniaux JC and Roger PP, The cyclic AMP-mediated stimulation of cell proliferation. Trends Pharmacol Sci 14: 67-71, 1989.
3. Cho-Chung YS, Role of cyclic AMP receptor proteins in growth, differentiation, and suppression of malignancy: new approaches to therapy. Cancer Res 50: 7093-7100, 1990.
4. Powis G, Signalling pathways as targets for anticancer drug development. Pharmacol Ther 62: 57-95, 1994.
5. Cho-Chung YS, Clair T, Tortora G and Yokozaki H, Role of site-selective cAMP analogs in the control and reversal of malignancy. Pharmacol Ther 50: 1-33, 1991.
6. Vittet D, Duperray C and Chevillard C, Cyclic-AMP inhibits cell growth and negatively interacts with platelet membrane glycoprotein expression on the Dami human megakaryoblastic cell line. J Cell Physiol 163: 645-655, 1995.
7. Levallois C, Bonnafous JC, Françoise MA, Sablayrolles C, Chapat JP and Mani JC, Theophylline-like properties of xanthine analogs. Biochem Pharmacol 33: 2253-2257, 1984.
8. Dress M, Zimmermann R and Eisenbrand G, 3′,5′-cyclic nucleotide phosphodiesterase in tumor cells as potential target for tumor growth inhibition. Cancer Res 53: 3058-3061, 1993.
9. Marcoz P, Prigent AF, Lagarde M and Nemoz G, Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents. Mol Pharmacol 44: 1027-1035, 1993.
10. Souness JE, Hassall GA and Parrott DP, Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors. Biochem Pharmacol 44: 857-866, 1992.
11. Takahashi S, Oida K, Fujiwara R, Maeda H, Hayashi S, Takai H, Tamai T, Nakai T and Miyabo S, Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J Cardiovasc Pharmacol 20: 900-906, 1992.
12. Banner KH and Page CP, Effect of type III and IV isoenzyme selective phosphodiesterase (PDE) inhibitors on proliferation of human peripheral blood mononuclear cells. Br J Pharmacol 113: 89P, 1994.
13. Pan X, Arauz E, Krzanowski JJ, Fitzpatrick DF and Poison JB, Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells. Biochem Pharmacol 48: 827-835, 1994.
14. Rathbone MP, Deforge S, Deluca B, Gabel B, Laurenssen C, Middlemiss P and Parkinson S, Purinergic stimulation of cell division and differentiation: mechanisms and pharmacological implications. Med Hypotheses 37: 213-219, 1992a.
15. Rathbone MP, Christjanson L, Deforge S, Deluca B, Gysbers JW, Hindley S, Jovetich M, Middlemiss P and Takhal S, Extracellular purine nucleosides stimulate cell division and morphogenesis: pathological and physiological implications. Med Hypotheses 37: 232-240, 1992b.
16. Bonnet PA, Michel A, Laurent F, Sablayrolles C, Rechencq E, Mani JC, Boucard M and Chapat JP, Synthesis and antibronchospastic activity of 8-alkoxy- and 8-(alkylamino) imidazo[1,2-α]-pyrazine. J Med Chem 35: 3353-3358, 1992.
17. Michel A, Laurent F, Chapat JP, Boucard M and Bonnet PA, Pharmacological activities of imidazo[1,2-α]pyrazine derivatives. Arzneimittelforschung 45: 1288-1293, 1995.
18. Laurent F, Pocock T, Elliot KRF, Portet K, Benezech V and Vitse O, Relaxant and phosphodiesterase inhibition activities of imidazo[1,2-α]pyrazine derivatives. Fundam Clin Pharmacol 10: 65, 1996.
19. Pocock TM and Small RC, Studies of the effects of SCA40 in relaxing bovine trachealis muscle and in inhibiting isoenzymes of cyclic nucleotide phosphodiesterase. Br J Pharmacol 117: 209P, 1996.
20. Zurbonsen K, Chevillard C, Vittet D, Bonnet PA and Michel A, Inhibition of human erythroleukemia (HEL) cell proliferation by imidazo[1,2-α]pyrazine derivatives. Fundam Clin Pharmacol 8: 260, 1994.
21. Zurbonsen K, Michel A, Vittet D, Bonnet PA, Gannoun-Zaki L, Mathieu MN and Chevillard C, Apoptotic effects of imidazo[1,2-α]pyrazine derivatives in human Dami cell line. Eur J Pharmacol, 320: 215, 1997.
22. Greenberg SM, Rosenthal DS, Greeley TA, Tantravahi R and Handin RI, Characterization of a new megakaryocytic cell line: the Dami cell. Blood 72: 1968-1977, 1988.
23. Decker T and Lohmann-Matthes ML, A quick and simple method for the quantification of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Methods 115: 61-69, 1988.
24. Thompson WJ, Terasaki W, Epstein PM and Strada SJ, Assay of cyclic nucleotide phophodiesterase and resolution of multiple molecular forms of the enzyme. Adv Cyclic Nucleotide Res 10: 69-92, 1979.
25. Cook SJ, Archer K, Martin A, Buchheit KH, Fozard JR, Müller T, Miller AJ, Elliot KRF, Foster RW and Small RC, Further analysis of the mechanisms underlying the tracheal relaxant action of SCA40. Br J Pharmacol 114: 143-151, 1995.
26. Tallarida RJ and Murray RB, Manual of pharmacologic calculation with computer programs. Springer Verlag, New York, 1981.
27. Viwanadhan VN, Ghose AK, Revankar GR and Robins RK, Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics. J Chem Inf Comput Sci 29: 163-172, 1989.
28. 2 purinoceptor-mediated responses. Eur J Pharmacol 217: 217-219, 1992.
29. + channel opening, of deaza-xanthine derivatives devoid of adenosine antagonism. Fundam Clin Pharmacol 5: 830, 1991.
30. 3H]2-MeS-ADP on megakaryocytoblastic cell lines in culture. Biochem Pharmacol 48: 83-86, 1994.
31. Tomes C, Rossi S and Moreno S, Isobutylmethylxanthine and other classical cyclic nucleotide phosphodiesterase inhibitors affect cAMP-dependent protein kinase activity. Cell Signal 5: 615-621, 1993.
32. Parsons WJ, Ramkumar V and Stiles GL, Isobutylmethylxanthine stimulates adenylate cyclase by blocking the inhibitory regulatory protein, Gi. Mol Pharmacol 34: 37-41, 1988.
33. Manganiello VC, Murata T, Taira M, Belfrage P and Degerman E, Perspectives in biochemistry and biophysics - diversity in cyclic nucleotide phosphodiesterase isoenzyme families. Arch Biochem Biophys 322: 1-13, 1995.
34. 2+ rise and phosphoinositide hydrolysis. Biochem J 234: 555-562, 1986.
35. Pyne NJ and Burns F, Lung phophodiesterase isoenzymes. Agents Actions Suppl 43: 35-49, 1993.
36. Burns F and Pyne NJ, Interaction of the catalytic subunit of protein kinase A with the lung type V cyclic GMP phosphodiesterase: modulation of non-catalytic binding sites. Biochem Biophys Res Commun 189: 1389-1396, 1992.